ALKS Alkermes Plc

Alkermes to Host Conference Call to Discuss Third Quarter 2016 Financial Results

Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.m. ET (12:30 p.m. GMT) on Wednesday, Nov. 2, 2016, to discuss the company’s third quarter 2016 financial results. Management will also provide an update on the company.

The conference call will be webcast on the Investors section of Alkermes’ website at www.alkermes.com or may be accessed by dialing +1 888 424 8151 for U.S. callers and +1 847 585 4422 for international callers. The conference call ID number is 6037988.

A replay of the conference call will be available from 11:00 a.m. ET (3:00 p.m. GMT) on Wednesday, Nov. 2, 2016, through 5:00 p.m. ET (10:00 p.m. GMT) on Wednesday, Nov. 9, 2016, and may be accessed by visiting Alkermes’ website or by dialing +1 888 843 7419 for U.S. callers and +1 630 652 3042 for international callers. The replay access code is 6037988.

About Alkermes plc

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

EN
26/10/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Alkermes Plc

Alkermes, Inc.: Update to credit analysis

Alkermes credit profile reflects its modest financial leverage and strong liquidity, offset by revenue concentration in three neuroscience-based products and approaching generic competition.

Moody's affirms Alkermes' Ba3 CFR, outlook stable

Moody's Investors Service ("Moody's") affirmed the ratings of Alkermes, Inc., a subsidiary of Alkermes plc (collectively "Alkermes"). The affirmed ratings include the Ba3 Corporate Family Rating, the Ba3-PD Probability of Default Rating, and the Ba3 senior secured term loan rating. There is no chang...

Alkermes, Inc.: Update to credit analysis

Our credit view of Alkermes reflects its good growth prospects on core products including Vivitrol, Aristada, and Lybalvi constrained by its pipeline execution and commercialization risk.

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 26, 2022

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch